Bilthoven Biologicals opens vaccine facilities

Netherlands-based Bilthoven Biologicals, the Dutch subsidiary of the Serum Institute of India and a leading end-to-end manufacturer of viral and bacterial vaccines, has officially inaugurated its pandemic preparedness vaccine facilities.

These facilities were established under the European Union (EU) pandemic preparedness project, EU FAB. The inauguration was attended by Laurent Muschel, director general of HERA at the European Commission, and Adar Poonawalla, chief executive of the Serum Institute of India.

This project aims to ensure vaccine accessibility for Europe in the event of a pandemic. Integrated within BBio’s existing end-to-end vaccine operations, these new facilities will have the capacity to produce more than 300 million doses annually during public health emergencies.